Bristol Myers Squibb spinout Beeline Medicines raised an additional $126.3 million through a Series A extension, bringing total capital to $426.3 million. The funding supports scaling its immune pipeline derived from BMS, including afimetoran in mid-stage lupus studies, and preparation for additional clinical starts spanning TYK2 and IL-18 receptor targeting.